SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-072728
Filing Date
2024-03-20
Accepted
2024-03-20 16:22:00
Documents
13
Period of Report
2024-03-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d797915d8k.htm   iXBRL 8-K 22568
  Complete submission text file 0001193125-24-072728.txt   140539

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cbay-20240318.xsd EX-101.SCH 2851
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE cbay-20240318_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cbay-20240318_pre.xml EX-101.PRE 10813
16 EXTRACTED XBRL INSTANCE DOCUMENT d797915d8k_htm.xml XML 3506
Mailing Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560
Business Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560 510-293-8800
CymaBay Therapeutics, Inc. (Filer) CIK: 0001042074 (see all company filings)

IRS No.: 943103561 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36500 | Film No.: 24768060
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)